Outpatient parenteral antimicrobial therapy in Germany: a prospective cohort study protocol.
GENERAL MEDICINE (see Internal Medicine)
INFECTIOUS DISEASES
Organisation of health services
Quality in health care
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
14 11 2022
14 11 2022
Historique:
entrez:
14
11
2022
pubmed:
15
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Outpatient parenteral antimicrobial therapy (OPAT) means intravenous administration of antibiotics outside the hospital. The antibiotics are administered at the patient's home. The advantages are the shortening of the inpatient stay, which means that patients can remain in their familiar environment, the reduction of nosocomial infections as well as the reduction of hospital and therapy costs. Nevertheless, OPAT is rarely performed in Germany, despite its international application. Therefore, systematic data on OPAT are not available in Germany. The project objective is to investigate the medical care using OPAT under medical, epidemiological and economic aspects within the framework of the Cologne Network of Infectious Diseases. Observational study with mixed-methods approach, qualitative analysis to identify physician-side factors to assess the attitude of general practitioners in Cologne with regard to possible implementation barriers of an OPAT. Longitudinal analysis of an OPAT patient cohort with respect to clinical and patient-relevant outcomes using descriptive and conclusive statistics. The study has been approved by the Institutional Review Board of the University of Cologne, Germany (19-1284-1). Written informed consent was obtained from all participants. The results will be submitted for publication in a peer-reviewed journal and presented at one or more scientific conferences. NCT04002453.
Identifiants
pubmed: 36375971
pii: bmjopen-2022-061417
doi: 10.1136/bmjopen-2022-061417
pmc: PMC9664305
doi:
Substances chimiques
Anti-Infective Agents
0
Anti-Bacterial Agents
0
Banques de données
ClinicalTrials.gov
['NCT04002453']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e061417Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S198-208
pubmed: 20731577
Int J Antimicrob Agents. 2017 Jul;50(1):114-118
pubmed: 28499957
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1387-1392
pubmed: 28283831
Int J Antimicrob Agents. 2011 Sep;38(3):243-8
pubmed: 21741221
Clin Infect Dis. 2004 Jun 15;38(12):1651-72
pubmed: 15227610
J Antimicrob Chemother. 2013 Jul;68(7):1650-4
pubmed: 23475647
Braz J Infect Dis. 2017 Nov - Dec;21(6):648-655
pubmed: 28711455
Int J Antimicrob Agents. 2012 May;39(5):407-13
pubmed: 22445493
Infection. 2020 Jun;48(3):357-366
pubmed: 32060859
Pharmacoeconomics. 2000 Nov;18(5):451-7
pubmed: 11151398
Eur J Intern Med. 2013 Oct;24(7):617-23
pubmed: 23602223
J Antimicrob Chemother. 2016 Feb;71(2):506-12
pubmed: 26510718
J Antimicrob Chemother. 2012 May;67(5):1053-62
pubmed: 22298347
N Z Med J. 2019 Aug 30;132(1501):21-32
pubmed: 31465324
Clin Infect Dis. 2019 Jan 1;68(1):e1-e35
pubmed: 30423035
Can Fam Physician. 1986 Nov;32:2366-8
pubmed: 21267217
Clin Infect Dis. 2018 Jan 6;66(1):11-19
pubmed: 29020202
Int J Antimicrob Agents. 2018 Jan;51(1):26-32
pubmed: 28673610